Outcomes of Men with Screen-Detected Prostate Cancer Eligible for Active Surveillance Who Were Managed Expectantly

European Urology

Volumn 55, Issue 1, 2009, Pages 1-8

  van den Bergh, Roderick C N ^a   Roemeling, Stijn ^a   Roobol, Monique J ^a   Aus, Gunnar ^b   Hugosson, Jonas ^b   Rannikko, Antti S ^c   Tammela, Teuvo L ^d   Bangma, Chris H ^a   Schröder, Fritz H ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^c HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^d TAMPERE UNIVERSITY HOSPITAL   (Finland)

Author keywords

Active surveillance; Doubling time; Outcome; Prognosis; Prostate cancer; PSA; Screening; Watchful waiting

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ACTIVE SURVEILLANCE; ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER GROWTH; CANCER INCIDENCE; CANCER SCREENING; CANCER SURVIVAL; COMORBIDITY; DISTRESS SYNDROME; DOUBLING TIME; FOLLOW UP; GLEASON SCORE; HUMAN; KAPLAN MEIER METHOD; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; PROSTATE BIOPSY; PROSTATE CANCER; PSYCHOLOGICAL ASPECT; RETROSPECTIVE STUDY; TIME; TREATMENT FREE SURVIVAL; WATCHFUL WAITING;

AGED; HUMANS; MALE; MIDDLE AGED; POPULATION SURVEILLANCE; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES;

EID: 56249097867     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2008.09.007     Document Type: Article

References (28)

1. Boyle P., Severi G., and Giles G.G. The epidemiology of prostate cancer. Urol Clin North Am 30 (2003) 209-217
2. Bryant R.J., and Hamdy F.C. Screening for prostate cancer: an update. Eur Urol 53 (2008) 37-44
3. Rietbergen J.B., Hoedemaeker R.F., Kruger A.E., Kirkels W.J., and Schroder F.H. The changing pattern of prostate cancer at the time of diagnosis: characteristics of screen detected prostate cancer in a population based screening study. J Urol 161 (1999) 1192-1198
4. Schröder F.H., Carter H.B., Wolters T., et al. Early detection of prostate cancer in 2007. Part 1: PSA and PSA kinetics. Eur Urol 53 (2008) 468-477
5. Albertsen P.C., Hanley J.A., and Fine J. 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA 293 (2005) 2095-2101
6. Harlan S.R., Cooperberg M.R., Elkin E.P., et al. Time trends and characteristics of men choosing watchful waiting for initial treatment of localized prostate cancer: results from CaPSURE. J Urol 170 (2003) 1804-1807
7. Penson D.F., McLerran D., Feng Z., et al. 5-year urinary and sexual outcomes after radical prostatectomy: results from the Prostate Cancer Outcomes Study. J Urol 179 (2008) S40-S44
8. Fransson P., and Widmark A. Late side effects unchanged 4-8 years after radiotherapy for prostate carcinoma: a comparison with age-matched controls. Cancer 85 (1999) 678-688
9. Parker C. Active surveillance: towards a new paradigm in the management of early prostate cancer. Lancet Oncol 5 (2004) 101-106
10. Roemeling S., Roobol M.J., de Vries S.H., et al. Active surveillance for prostate cancers detected in three subsequent rounds of a screening trial: characteristics, PSA doubling times, and outcome. Eur Urol 51 (2007) 1244-1251 (discussion 1251)
11. Bratt O. Watching the face of Janus - active surveillance as a strategy to reduce overtreatment for localised prostate cancer. Eur Urol 50 (2006) 410-412
12. Finne P., Stenman U.H., Maattanen L., et al. The Finnish trial of prostate cancer screening: where are we now?. BJU Int 92 Suppl 2 (2003) 22-26
13. Schröder F.H., Denis L.J., Roobol M., and and all participants of the ERSPC. The story of the European Randomized Study of Screening for Prostate Cancer. BJU Int 92 Suppl 2 (2003) 1-13
14. Van den Bergh R.C.N., Roemeling S., Roobol M.J., Roobol W., Schröder F.H., and Bangma C.H. Prospective validation of active surveillance in prostate cancer: the PRIAS study. Eur Urol 52 (2007) 1560-1563
15. Choo R., Klotz L., Danjoux C., et al. Feasibility study: watchful waiting for localized low to intermediate grade prostate carcinoma with selective delayed intervention based on prostate specific antigen, histological and/or clinical progression. J Urol 167 (2002) 1664-1669
16. Freedland S.J., Sutter M.E., Dorey F., and Aronson W.J. Defining the ideal cutpoint for determining PSA recurrence after radical prostatectomy. Prostate-specific antigen. Urology 61 (2003) 365-369
17. Horwitz E.M., Thames H.D., Kuban D.A., et al. Definitions of biochemical failure that best predict clinical failure in patients with prostate cancer treated with external beam radiation alone: a multi-institutional pooled analysis. J Urol 173 (2005) 797-802
18. Makinen T., Karhunen P., Aro J., Lahtela J., Maattanen L., and Auvinen A. Assessment of causes of death in a prostate cancer screening trial. Int J Cancer 122 (2008) 413-417
19. Roemeling S., Roobol M.J., Postma R., et al. Management and survival of screen-detected prostate cancer patients who might have been suitable for active surveillance. Eur Urol 50 (2006) 475-482
20. Ramirez M.L., Nelson E.C., deVere White R.W., Lara Jr. P.N., and Evans C.P. Current applications for prostate-specific antigen doubling time. Eur Urol 54 (2008) 291-302
21. Hardie C., Parker C., Norman A., et al. Early outcomes of active surveillance for localized prostate cancer. BJU Int 95 (2005) 956-960
22. Johansson J.E., Andren O., Andersson S.O., et al. Natural history of early, localized prostate cancer. JAMA 291 (2004) 2713-2719
23. Albertsen P.C., Hanley J.A., Gleason D.F., and Barry M.J. Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer. JAMA 280 (1998) 975-980
24. Draisma G., Boer R., Otto S.J., et al. Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst 95 (2003) 868-878
25. Albertsen P.C., Hanley J.A., Barrows G.H., et al. Prostate cancer and the Will Rogers phenomenon. J Natl Cancer Inst 97 (2005) 1248-1253
26. Carter C.A., Donahue T., Sun L., et al. Temporarily deferred therapy (watchful waiting) for men younger than 70 years and with low-risk localized prostate cancer in the prostate-specific antigen era. J Clin Oncol 21 (2003) 4001-4008
27. Latini D.M., Hart S.L., Knight S.J., et al. The relationship between anxiety and time to treatment for patients with prostate cancer on surveillance. J Urol 178 (2007) 826-831 discussion 831-2
28. National Institute for Public Health and the Environment. Research for man and environment. http://www.rivm.nl. Accessed June 25, 2008.